Abstract
We performed SEREX (serological analysis of recombinant cDNA expression library) to identify autoantibodies that are prevalent in the cerebrospinal fluid of patients with moyamoya disease. These autoantibodies include PC326 (of unknown function), SRY (sex determining region Y), and peroxisomal D3,D2-enoyl-CoA isomerase.
Similar content being viewed by others
References
Geisbrecht BV, Zhang D, Schulz H, Gould SJ (1999) Characterization of PECI, a novel monofunctional delta-3, delta-2-enoyl-CoA isomerase of mammalian peroxisomes. J. Biol. Chem. 274: 21797–21803.
Giese K, Pagel J, Grosschedl R (1994) Distinct DNA-binding properties of the high mobility group domain of murine and human SRY sex-determining factors. Proc. Natl. Acad. Sci. 91: 3368–3372.
Hallenbeck JM, Dutka AJ, Tanishima T, Kochanek PM, Kumaroo KK, Thompson CB, Obrenovitch TP, Contreras TJ (1985) Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period. Stroke 17: 246–253.
LimY, LeeDY, Lee S, Park SY, Kim J, Cho B, Lee H, Kim HY, Lee E, Song YW, Jeoung DI (2002) Identification of autoantibodies associated with systemic lupus erythematosus. Biochem. Biophys. Res. Commun. 295: 119–124.
Malek AM, Connors S, Robertson RL, Folkman J, Scott RM (1997) Elevation of cerebrospinal fluid levels of fibroblast growth factor in moyamoya and central system disorders. Pediatr. Neurosurg. 27: 182–189.
Shetty-Alva N, Alva S (2000) Familial moyamoya disease in Caucasians. Pediatr. Neurol. 23: 2513–2517.
Soriano SG, Cowan DB, Proctor MR, Scott RM (2002) Levels of soluble adhesion molecules are elevated in the cerebrospinal fluid of children with moyamoya syndrome. Neurosurgery 50: 544–549.
Suzuki K, Takaku A (1969) Cerebrovascular 'moyamoya' disease: disease showing abnormal net-like vessels in the base of brain. Arch. Neurol. 20: 288–299.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kim, J., Kim, SK., Wang, KC. et al. SEREX identification of the autoantibodies that are prevalent in the cerebrospinal fluid of patients with moyamoya disease. Biotechnology Letters 26, 585–588 (2004). https://doi.org/10.1023/B:BILE.0000021961.79459.53
Issue Date:
DOI: https://doi.org/10.1023/B:BILE.0000021961.79459.53